Digest Réseau Comment ça marche
Réseau
/
Sociétés
Io
Non vérifié

Io Therapeutics, Inc.

Ce que nous écrivons

Annonces ÉconomiquesBiotechnologieMédecine Santé Bien-être

5 communiqués de presse

Voir tous les communiqués de presse
11/12/2025
Biotechnologie
Médecine Santé Bien-être
Io Therapeutics, Inc., presents today at the San Antonio Breast Cancer Symposium preclinical studies demonstrating effectiveness of IRX4204, the company’s clinical stage retinoid X nuclear receptor (RXR) agonist compound, for synergistically promoting killing of HER2+ breast cancer cells in combination with HER2-targeted chimeric antigen receptor modified T-cells (CAR-T).
Source
Io Therapeutics, Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
06/12/2025
Biotechnologie
Io Therapeutics presents today at the American Society for Hematology Annual Meeting, preclinical studies demonstrating combination treatment with BCMA CAR-T cells plus the company's RXR agonist compound IRX4204 has synergistic efficacy against human multiple myeloma
Source
Io Therapeutics, Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
23/12/2024
Biotechnologie
Scientists report studies showing a novel drug repairs myelin and restores nervous system function in a model of multiple sclerosis
Source
Io Therapeutics, Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
11/12/2024
Biotechnologie
Médecine Santé Bien-être
Annonces Économiques
Io Therapeutics, Inc., announces presentation of data from studies of its RAR gamma agonist compound IRX5010 in treatment of a mouse model of triple negative breast cancer, demonstrating combination treatment effects with an anti-PDL-1 monoclonal antibody checkpoint inhibitor
Source
Io Therapeutics, Inc.
Émetteur
GLOBENEWSWIRE
1.00
0
08/11/2024
Biotechnologie
Io Therapeutics, Inc., announces presentation of data on its RAR gamma agonist compound IRX5010 demonstrating inhibition of tumor infiltrating myeloid derived suppressor cells, promotion of tumor infiltrating T-cells, and effective tumor growth inhibition in murine models of breast, colorectal, and prostate cancers
Source
Io Therapeutics, Inc.
Émetteur
GLOBENEWSWIRE
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0